2020 Pediatric Rheumatology Symposium

April 29-May 2, 2020

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

View by Number View by Title View Sessions

View by Date

Abstract Number: 061

Perspectives of Radiologist Physicians in the Imaging of Chronic Nonbacterial Osteomyelitis
Abstract Number: 062

Is Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) a Reliable Tool for Detecting Vascular Activity in Treated Childhood-Onset Takayasu’s Arteritis (C-TA)? A Multicenter Study
Abstract Number: 063

Musculoskeletal Ultrasound Assessment in Pediatric Knee Hypermobility
Abstract Number: 064

The First 18 Months of a Pediatric Rheumatology Service at a Tertiary Referral Hospital in Kenya
Abstract Number: 065

Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis
Abstract Number: 066

Baseline Kidney Biopsy in Lupus Patients Without Renal Manifestations. Underappreciated or Overrated?
Abstract Number: 067

Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis
Abstract Number: 068

Development of CARRA Consensus Treatment Plans for Severe ANCA-associated Vasculitis – Final CARRA-wide Consensus
Abstract Number: 069

Rheumatic Fever in a Tertiary Medical Center – 25 Years of Follow Up
Abstract Number: 070

The Importance of the Patient Global Health Assessment of Disease Activity in Polyarticular Juvenile Idiopathic Arthritis
Abstract Number: 071

Patient Reported Outcomes and Resilience in Pediatric Systemic Lupus Erythematosus
Abstract Number: 072

Allogenic Hematopoietic Stem Cell Transplantation for Refractory Childhood Rheumatic Diseases
Abstract Number: 073

Differences in Clinical Presentation Between Israeli and United States Children with Juvenile Spondyloarthritis
Abstract Number: 074

Establishment of a Registry for Juvenile Idiopathic Arthritis (JIA) Patients in South Australia (SA): Focus on Patient Reported Outcome Measures (PROMs) and Experiences (PREMs)
Abstract Number: 075

Pseudotumor Cerebri Syndrome in Children with Systemic Lupus Erythematosus

« Previous Page
1
…
3
4
5
6
7
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].